Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-Infected Subjects on Antiretroviral Therapy: The SATURN-HIV Trial

被引:38
作者
Longenecker, Chris T. [1 ,2 ]
Hileman, Corrilynn O. [1 ,3 ]
Funderburg, Nicholas T. [4 ]
McComsey, Grace A. [1 ,2 ]
机构
[1] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
[2] Univ Hosp Case Med Ctr, Cleveland, OH USA
[3] Metrohlth Med Ctr, Cleveland, OH USA
[4] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
statin; HIV; cystatin C; kidney; inflammation; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; T-CELL-ACTIVATION; ESTIMATING EQUATIONS; MONOCYTE ACTIVATION; STATIN THERAPY; INFLAMMATION; MARKERS; ATORVASTATIN; ASSOCIATION;
D O I
10.1093/cid/ciu523
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In chronic human immunodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glomerular filtration rate such as inflammation. Statins may improve cystatin C by improving glomerular function or by decreasing inflammation. Methods. The Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy (ART) with low-density lipoprotein cholesterol <= 130 mg/dL to blinded 10 mg daily rosuvastatin or placebo. We analyzed relationships of baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disease, inflammation, and immune activation. Results. Median age was 46 (interquartile range, 40-53) years; 78% were male, 68% African American. Tenofovir and protease inhibitors were used in 88% and 49% of subjects, respectively. Baseline cystatin C was associated with higher carotid intima-media thickness and epicardial adipose tissue independent of age, sex, and race. Biomarkers of endothelial activation and inflammation were associated with cystatin C in a multivariable model independent of creatinine-based estimated glomerular filtration rate (eGFR(cr)). After 24 weeks, statin use slowed mean eGFR(cr) decline (1.61 vs -3.08 mL/minute/1.73 m(2) for statin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008). Within the statin group, changes in cystatin C correlated with changes in endothelial activation, inflammation, and T-cell activation. Conclusions. Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infected patients on ART. Reductions in cystatin C with statin therapy correlate with reductions in inflammatory biomarkers. Relationships between cystatin C, kidney function, and cardiovascular risk in HIV may be mediated in part by inflammation.
引用
收藏
页码:1148 / 1156
页数:9
相关论文
共 40 条
  • [1] High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors
    Aslangul, Elisabeth
    Fellahi, Soraya
    Assoumou, Lambert K.
    Bastard, Jean-Philippe
    Capeau, Jacqueline
    Costagliola, Dominique
    [J]. AIDS, 2011, 25 (08) : 1128 - 1131
  • [2] Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial
    Baker, Jason V.
    Hullsiek, Kathleen Huppler
    Prosser, Rachel
    Duprez, Daniel
    Grimm, Richard
    Tracy, Russell P.
    Rhame, Frank
    Henry, Keith
    Neaton, James D.
    [J]. PLOS ONE, 2012, 7 (10):
  • [3] HIV Viremia and T-Cell Activation Differentially Affect the Performance of Glomerular Filtration Rate Equations Based on Creatinine and Cystatin C
    Bhasin, Bhavna
    Lau, Bryan
    Atta, Mohamed G.
    Fine, Derek M.
    Estrella, Michelle M.
    Schwartz, George J.
    Lucas, Gregory M.
    [J]. PLOS ONE, 2013, 8 (12):
  • [4] The impact of HIV on chronic kidney disease outcomes
    Choi, A. I.
    Rodriguez, R. A.
    Bacchetti, P.
    Bertenthal, D.
    Volberding, P. A.
    O'Hare, A. M.
    [J]. KIDNEY INTERNATIONAL, 2007, 72 (11) : 1380 - 1387
  • [5] Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons
    Choi, Andy
    Scherzer, Rebecca
    Bacchetti, Peter
    Tien, Phyllis C.
    Saag, Michael S.
    Gibert, Cynthia L.
    Szczech, Lynda A.
    Grunfeld, Carl
    Shlipak, Michael G.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (05) : 872 - 882
  • [6] Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons
    Choi, Andy I.
    Li, Yongmei
    Deeks, Steven G.
    Grunfeld, Carl
    Volberding, Paul A.
    Shlipak, Michael G.
    [J]. CIRCULATION, 2010, 121 (05) : 651 - 658
  • [7] Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients
    Cooper, Ryan D.
    Wiebe, Natasha
    Smith, Nathaniel
    Keiser, Philip
    Naicker, Saraladevi
    Tonelli, Marcello
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) : 496 - 505
  • [8] Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis
    Dubin, Ruth
    Shlipak, Michael
    Li, Yongmei
    Ix, Joachim
    de Boer, Ian H.
    Jenny, Nancy
    Peralta, Carmen A.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (06) : 1903 - 1908
  • [9] Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy
    Eckard, Allison Ross
    Jiang, Ying
    Debanne, Sara M.
    Funderburg, Nicholas T.
    McComsey, Grace A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (08) : 1156 - 1164
  • [10] Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087
    Fichtenbaum, Carl J.
    Yeh, Tzu-Min
    Evans, Scott R.
    Aberg, Judith A.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (04) : 279 - 287